BIOL Past Earnings image   This BIOL past earnings page last updated 8/15/2022
BIOL Past Earnings
PeriodPast Earnings DateGAAP
Q2 20228/11/2022-0.910
Q1 20225/12/2022-0.770
Q4 20213/17/2022-0.750
Q3 202111/10/2021-0.500
Q2 20218/12/2021-0.500
Q1 20215/13/2021-1.500
Q4 20203/25/2021-1.750
Q3 202011/12/2020-5.250
Q2 20208/13/2020-3.000
Q1 20205/7/2020-4.750
Q4 20193/26/2020-3.250
Q3 201911/6/2019-6.250
Q2 20198/8/2019-3.250
Q1 20195/9/2019-3.750
Q4 20183/5/2019-3.250
Q3 201811/13/2018-4.750
Q2 20188/8/2018-5.000
Q1 20185/2/2018-1.000
Q4 20173/14/2018-1.000
Q3 201711/1/2017-1.250
Q2 20178/7/2017-1.250
Q1 20175/3/2017-1.250
Q4 20163/8/2017-1.250
Q3 201611/8/2016-1.000
Q2 20168/1/2016-1.000
Q1 20165/9/2016-1.500
Q4 20153/9/2016-0.500
Q3 201511/4/2015-2.000
Q2 20158/5/2015-2.500
Q1 20154/30/2015-0.08
Q4 20143/4/2015-0.06
Q3 201411/4/2014-0.07
Q2 20148/7/2014-0.17
Q1 20145/12/2014-0.11
Q4 20133/5/2014-0.04
Q3 201311/11/2013-0.1
Q2 20138/7/2013-0.06
Q1 20135/7/2013-0.06
Q4 20123/6/20130.03
Q3 201211/5/2012-0.02
Q2 20128/8/2012-0.04
BIOL Past Revenue
PeriodPast Earnings DateGAAP
Q2 20228/11/20220.01B
Q1 20225/12/20220.01B
Q4 20213/17/20220.01B
Q3 202111/10/20210.01B
Q2 20218/12/20210.01B
Q1 20215/13/20210.01B
Q4 20203/25/20210.01B
Q3 202011/12/20200.01B
Q2 20208/13/20200.00B
Q1 20205/7/20200.00B
Q4 20193/26/20200.01B
Q3 201911/6/20190.01B
Q2 20198/8/20190.01B
Q1 20195/9/20190.01B
Q4 20183/5/201913.04M
Q3 201811/13/201810.94M
Q2 20188/8/201812.15M
Q1 20185/2/201810.02M
Q4 20173/14/201812.63M
Q3 201711/1/201710.81M
Q2 20178/7/201712.61M
Q1 20175/3/201710.87M
Q4 20163/8/201713.76M
Q3 201611/8/201613.23M
Q2 20168/1/201613.81M
Q1 20165/9/201611.01M
Q4 20153/9/201614.52M
Q3 201511/4/201511.23M
Q2 20158/5/201511.87M
Q1 20154/30/201510.86M
Q4 20143/4/201513.24M
Q3 201411/4/201412.70M
Q2 20148/7/201410.20M
Q1 20145/12/201411.50M
Q4 20133/5/201415.20M
Q3 201311/11/201312.30M
Q2 20138/7/201314.20M
Q1 20135/7/201314.60M
Q4 20123/6/201319.10M
Q3 201211/5/201213.78M
Q2 20128/8/20120.01B
Quotes delayed 20 minutes

Email EnvelopeFree BIOL Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Biolase (BIOL) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

BIOR Past Earnings
BIVI Past Earnings
BKD Past Earnings
BLCM Past Earnings
BLFS Past Earnings
BLI Past Earnings
BLPH Past Earnings
BLUE Past Earnings
BMEA Past Earnings
BMRA Past Earnings

BIOL Past Earnings Q&A

What was the best and worst BIOL past earnings results?
For Biolase, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest BIOL past earnings result in our data set was 0.03/share posted in Q4 2012, while the lowest was in Q3 2019 when BIOL posted -6.250/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q4 2012 when BIOL reported 19.10M in revenue, while the quarter with the lowest revenue in our data set was Q2 2020 at 0.00B of revenue.

  Suggested answer: There are 41 BIOL past earnings results in our data set.

On this page we presented the BIOL past earnings date information for Biolase. Reviewing that BIOL Past Earnings for the company, we see that the highest past earnings result in our data set was in Q4 2012, when BIOL posted gaap of 0.03/share. Meanwhile the lowest BIOL past earnings result was in Q3 2019, when BIOL posted gaap of -6.250/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q4 2012 when BIOL reported 19.10M in revenue, while the smallest revenue quarter was Q2 2020 when BIOL reported 0.00B in revenue.

Any self directed investor doing their due diligence on BIOL or any other given stock can benefit from researching all of the Biolase past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate Biolase past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for BIOL. Thanks for visiting, and the next time you need to research BIOL past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: WAB Options Chain, TYPE Historical Stock Prices, TSIBU Historical Stock Prices.

 

BIOL Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.